I-Loki Therapeutics namuhla imemezele ukushicilelwa kocwaningo kumagazini, "Isayensi Yokuhumusha Imithi", ebonisa amandla e-AWAKE-LM-TT ekwelapheni umdlavuza we-pancreatic. I-AWAKE-LM-TT, eyakhiwe nguClaudia Gravekamp, Ph.D., Umsunguli Ka-Loki kanye Noprofesa Ohlangene We-Microbiology & Immunology e-Albert Einstein School of Medicine, igxile ekugomeni kwengane ye-tetanus ukuze ikhiqize amasosha omzimba anamandla futhi asheshayo. ukuphendula kumathumba aqinile kanye nama-metastase ethula ama-antigen e-tetanus.
Umbhalo wesandla onesihloko esithi, "I-Listeria Ihambisa I-Tetanus Toxoid Protein kuma-Pancreatic Tumors futhi Idala Ukufa Kweseli Lomdlavuza Emagundaneni," futhi eyabhalwa ngokubambisana nguDkt. Gravekamp, Ph.D., ichaza ucwaningo oluhilela indlela entsha yokwelapha umdlavuza we-pancreatic lapho i-Listeria monocytogenes yenziwa khona. esetshenziselwa ukuletha amaprotheni e-immunogenic tetanus toxoid (TT) ngqo kumaseli wesimila. Lokhu kulethwa, i-Listeria-TT, kuboniswe ukuthi kuletha impendulo yokuzivikela komzimba, kusebenze amaseli e-tetanus toxoid-specific memory T ukuze abulale amaseli e-pancreatic ductal adenocarcinoma (PDAC) kumagundane. Lapho kuhlanganiswa ne-gemcitabine (Listeria-TT + GEM), abacwaningi babone ukwehliswa ngo-80% komthwalo wesimila se-PDAC kanye nokwehliswa kwama-metastase ngama-87% ngokunyuka kokusinda ngo-40% uma kuqhathaniswa namagundane angelashiwe, okuphakamisa ukuthi ama-antigens okukhumbula alethwe i-Listeria angahle enye indlela ye-neoantigen-mediated cancer immunotherapy.
Umsunguli we-Loki Co-founder kanye ne-CEO uChris Bradley uthe, "Lolu cwaningo luyiphuzu nje uma kuziwa ekuhlonzeni nasekutholeni imithi esebenzayo yokwelapha umdlavuza onzima. Umdlavuza we-pancreatic kunzima ukuwubona kusenesikhathi, okwenza ukuthola ukwelashwa kube inselele nakakhulu, ngoba ngokuvamile utholakala esigabeni esithuthukile noma sekwephuzile. Lolu cwaningo lukhombisa amandla abalulekile e-Loki's AWAKE-LM-TT njengokwelashwa okunoveli komdlavuza we-pancreatic uma kunikezwe ikhono layo lokusebenzisa umuthi wokugomela i-tetanus toxoid ukuze ukhiqize impendulo enamandla nesheshayo yokuzivikela komzimba kumathumba aqinile kanye nama-metastase ethula ama-antigens e-tetanus.
UDkt. Gravekamp uphawule wathi, “Ngenxa yalolu cwaningo, sinesu elisha elingeke libe nje kuphela ukwelapha okuphumelelayo kwamasosha omzimba ekwelapheni umdlavuza wamanyikwe, kodwa neminye imidlavuza. Izimila ze-pancreatic ziyinselele kakhulu ukwelapheka ngokuthi, emasosheni omzimba, lawa mathumba awabonakali ngokwanele 'angaphandle' ukuze adonse ukunaka kwamasosha omzimba futhi ngokuvamile angacindezela noma yikuphi ukusabela komzimba okwenzekayo. Indlela yethu empeleni yenza lezi zimila 'ezibandayo' ezivikela umzimba zishise ngokwanele ukuze amasosha omzimba ahlasele futhi abhubhise.”
U-Loki ulungiselela ukufaka isicelo se-Investigational New Drug (IND) ne-US Food & Drug Administration sohlelo lomtholampilo lokuqala kumuntu oluphenya i-AWAKE-LM-TT ekwelapheni umdlavuza wamabele. Lapho ethola imvume ye-FDA ye-IND, u-Loki ulindele ukuqalisa ukuhlolwa komtholampilo kweSigaba 1 engxenyeni yesibili ka-2022.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- This research demonstrates the significant potential of Loki’s AWAKE-LM-TT as a novel treatment for pancreatic cancer given its ability to harness the childhood vaccination for tetanus toxoid to generate a powerful and immediate immune response to solid tumors and metastases presenting the tetanus antigens.
- Pancreatic cancer is difficult to identify at an early stage, which makes finding a treatment even more challenging, since it is usually detected at an advanced or late stage.
- When combined with gemcitabine (Listeria-TT + GEM), researchers observed an 80% reduction of PDAC tumor burden and an 87% reduction of metastases with an increased survival by 40% compared to nontreated mice, suggesting that Listeria-delivered recall antigens could be an alternative to neoantigen-mediated cancer immunotherapy.
